olivLaw · US equity research
UroGen Pharma Ltd. URGN
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
At the close of 04 Nov 2026, UroGen Pharma Ltd. (URGN) stock was 28.74 USD (−16.45% on the day), with market capitalisation 1.4 bn USD, beta 1.15, 52-week range 17.00–50.29 USD. Latest reported quarter (Q3 2026): revenue of 89.0 m USD (+223.9% YoY), net income of -1.5 m USD, diluted EPS -0.03 USD.
Data as of · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 23.5
- oversold (≤ 30)
- Bollinger (20, 2)
- 30.74 – 39.04
- below the lower band · %B -0.24 · band width 23.8%
- SMA 50 / 200
- 39.60 / 31.51
- mixed trend
- MACD (12, 26, 9)
- -2.19 / -2.01
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −32.8% | −1.1% | −31.7 pp | — |
| 3 months | −38.1% | −0.5% | −37.6 pp | — |
| 6 months | +9.5% | +4.4% | +5.1 pp | — |
| Year to date | +22.7% | +12.3% | +10.4 pp | — |
| 1 year | +45.1% | +13.5% | +31.5 pp | −10.4% |
| 3 years | +148.4% | +76.4% | +72.0 pp | +38.4% |
| 5 years | +57.8% | +63.7% | −5.8 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 24.6 m | 20.3 m | 24.2 m | 27.5 m | 37.8 m | 51.0 m | 72.5 m | 89.0 m |
| Cost of revenue | 2.5 m | 2.3 m | 3.6 m | 3.3 m | 3.3 m | 4.1 m | 6.6 m | 7.5 m |
| Gross profit | 22.1 m | 17.9 m | 20.7 m | 24.2 m | 34.5 m | 46.8 m | 65.9 m | 81.5 m |
| Research & development | 14.9 m | 19.9 m | 18.9 m | 14.0 m | 14.3 m | 15.6 m | 17.3 m | 26.0 m |
| SG&A | 34.9 m | 35.0 m | 43.2 m | 37.6 m | 39.3 m | 51.5 m | 48.4 m | 47.2 m |
| Operating income | -27.7 m | -36.9 m | -41.4 m | -27.4 m | -19.1 m | -20.3 m | 111.0 k | 8.3 m |
| Depreciation & amortisation | 68.0 k | 72.0 k | 100.0 k | 100.0 k | 75.0 k | 75.0 k | 100.0 k | 100.0 k |
| Pre-tax income | -34.9 m | -43.5 m | -48.9 m | -34.4 m | -26.6 m | -28.3 m | -8.7 m | -446.0 k |
| Income tax | 2.6 m | 392.0 k | 1.0 m | -1.1 m | -275.0 k | -4.8 m | 5.6 m | 1.0 m |
| Net income | -37.5 m | -43.8 m | -49.9 m | -33.3 m | -26.4 m | -23.6 m | -14.4 m | -1.5 m |
| Diluted EPS | -0.80 | -0.92 | -1.05 | -0.69 | — | -0.47 | -0.28 | -0.03 |
| Operating cash flow | -13.6 m | -42.0 m | -39.8 m ≈ | -42.3 m ≈ | -38.3 m | -45.3 m | -33.0 m ≈ | -15.2 m ≈ |
| Capex | 115.0 k | 44.0 k | 141.0 k ≈ | 87.0 k ≈ | 17.0 k | 54.0 k | 60.0 k ≈ | 72.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1 m | 18.0 k | 11.8 m | 48.0 m | 64.4 m | 82.7 m | 90.4 m | 109.8 m |
| Revenue YoY | −86.2% | −98.4% | +65,450.0% | +307.2% | +34.0% | +28.5% | +9.3% | +21.4% |
| Net income | -75.7 m | -105.1 m | -128.5 m | -110.8 m | -109.8 m | -102.2 m | -126.9 m | -153.5 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable | -4.96 | -4.81 | -3.55 | -2.96 | -3.19 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -6,707.2% | -584,144.4% | -1,088.9% | -230.7% | -170.6% | -123.6% | -140.4% | -139.8% |
| Free cash flow | -37.9 m | -71.3 m | -107.1 m | -85.6 m | -87.8 m | -76.6 m | -97.1 m | -162.7 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 110.7 m USD
- Financial debt
- 122.2 m USD
- Net debt
- 11.5 m USD
- Equity
- -105.5 m USD
- Total assets
- 200.5 m USD
- Debt / equity
- unavailable
- Current ratio
- 4.01x
- ROE
- unavailable
- ROA
- -63.1%
- FCF margin
- -148.2%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 11.8 m | 48.0 m | 64.4 m | 82.7 m | 90.4 m | 109.8 m | SEC (XBRL)· 02 Mar 2026verified |
| Cost of revenue | 1.0 m | 5.2 m | 7.7 m | 9.4 m | 8.9 m | 12.4 m | SEC (XBRL)· 02 Mar 2026verified |
| Gross profit | 10.8 m | 42.9 m | 56.7 m | 73.4 m | 81.5 m | 97.3 m | SEC (XBRL)· 02 Mar 2026verified |
| Research & development | 47.3 m | 47.6 m | 52.9 m | 45.6 m | 57.1 m | 67.1 m | SEC (XBRL)· 02 Mar 2026verified |
| SG&A | 90.2 m | 87.5 m | 82.8 m | 93.3 m | 121.2 m | 155.1 m | SEC (XBRL)· 02 Mar 2026verified |
| Operating income | -126.7 m | -92.3 m | -79.0 m | -65.5 m | -96.8 m | -124.9 m | SEC (XBRL)· 02 Mar 2026verified |
| Depreciation & amortisation | 416.0 k | 831.0 k | 924.0 k | 802.0 k | 329.0 k | 307.0 k | SEC (XBRL)· 02 Mar 2026verified |
| EBITDA | -126.3 m ≈ | -91.5 m ≈ | -78.1 m ≈ | -64.7 m ≈ | -96.5 m ≈ | -124.6 m ≈ | SEC (XBRL)· 02 Mar 2026derived |
| Pre-tax income | -125.1 m | -109.4 m | -108.0 m | -98.3 m | -124.0 m | -153.4 m | SEC (XBRL)· 02 Mar 2026verified |
| Income tax | 3.4 m | 1.4 m | 1.8 m | 3.9 m | 2.8 m | 78.0 k | SEC (XBRL)· 02 Mar 2026verified |
| Net income | -128.5 m | -110.8 m | -109.8 m | -102.2 m | -126.9 m | -153.5 m | SEC (XBRL)· 02 Mar 2026verified |
| Diluted EPS | — | -4.96 | -4.81 | -3.55 | -2.96 | -3.19 | SEC (XBRL)· 02 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 52.9 m | 44.4 m | 55.4 m | 95.0 m | 172.0 m | 110.7 m | SEC (XBRL)· 02 Mar 2026verified |
| Receivables | 7.0 m | 11.7 m | 12.7 m | 15.4 m | 20.3 m | 33.1 m | SEC (XBRL)· 02 Mar 2026verified |
| Inventories | 2.0 m | 4.8 m | 4.3 m | 5.7 m | 9.2 m | 16.5 m | SEC (XBRL)· 02 Mar 2026verified |
| Current assets | 115.6 m | 114.4 m | 128.9 m | 169.2 m | 276.1 m | 186.0 m | SEC (XBRL)· 02 Mar 2026verified |
| Property, plant & equipment, net | 2.0 m | 2.0 m | 1.3 m | 689.0 k | 655.0 k | 637.0 k | SEC (XBRL)· 02 Mar 2026verified |
| Total assets | 122.0 m | 119.7 m | 135.6 m | 178.3 m | 285.7 m | 200.5 m | SEC (XBRL)· 02 Mar 2026verified |
| Accounts payable | 3.3 m | 5.8 m | 5.5 m | 6.5 m | 10.9 m | 12.1 m | SEC (XBRL)· 02 Mar 2026verified |
| Long-term debt | — | 0 | 97.5 m | 98.6 m | 121.7 m | 122.2 m | SEC (XBRL)· 02 Mar 2026verified |
| Current liabilities | 21.4 m | 22.4 m | 23.9 m | 31.2 m | 45.9 m | 46.4 m | SEC (XBRL)· 02 Mar 2026verified |
| Total liabilities | 25.7 m | 111.3 m | 225.0 m | 243.5 m | 294.5 m | 305.9 m | SEC (XBRL)· 02 Mar 2026verified |
| Equity | 96.4 m † | 8.4 m † | -89.4 m † | -65.2 m † | -8.8 m † | -105.5 m † | SEC (XBRL)· 02 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -105.9 m | -84.9 m | -87.6 m | -76.4 m | -96.8 m | -162.4 m | SEC (XBRL)· 02 Mar 2026verified |
| Capex | 1.2 m | 752.0 k | 254.0 k | 194.0 k | 295.0 k | 289.0 k | SEC (XBRL)· 02 Mar 2026verified |
| Free cash flow | -107.1 m ≈ | -85.6 m ≈ | -87.8 m ≈ | -76.6 m ≈ | -97.1 m ≈ | -162.7 m ≈ | SEC (XBRL)· 02 Mar 2026derived |
| Investing cash flow | 93.2 m | 4.1 m | 1.1 m | -953.0 k | -20.6 m | 61.6 m | SEC (XBRL)· 02 Mar 2026verified |
| Financing cash flow | 16.5 m | 72.3 m | 97.1 m | 116.9 m | 194.6 m | 39.9 m | SEC (XBRL)· 02 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 27.1% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1.4 bn USD
Key indicators
Coverage and freshness
Score by group
27% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -26.3% | 35 (vs peers) | 23% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 19.5% | 100 (on a fixed band) | 31% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 3.4x | 100 (on a fixed band) | 15% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -9.4% | 0 (on a fixed band) | 31% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial35/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
UroGen Pharma Ltd. (URGN). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 109.8 m USD in 2025; YoY growth 21.4%; net margin -26.3%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 19.5%
- Current ratio: 3.4x
What contradicts it
- FCF yield: -9.4%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,334.0 bn | 46.0 | 86.1% | 31.9% | +44.7% | +32% / +140% |
| JNJJohnson & Johnson | 665.2 bn | 41.9 | 20.0% | 16.2% | +6.0% | +34% / +79% |
| ONCBeone Medicines Ltd. | 558.4 bn | 869.9 | 14.7% | 10.7% | +40.2% | +11% / +102% |
| ABBVAbbVie Inc. | 521.1 bn | 50.7 | — | 15.7% | +8.6% | +29% / +107% |
| MRKMerck & Co., Inc. | 370.7 bn | 154.7 | 5.1% | 3.6% | +1.3% | +43% / +47% |
| ABTAbbott Laboratories | 200.1 bn | 43.0 | 9.2% | 9.7% | +5.7% | −10% / +11% |
| PFEPfizer Inc | 175.5 bn | 43.9 | 4.4% | 6.3% | −1.6% | +20% / +1% |
| VRTXVertex Pharmaceuticals Inc | 139.2 bn | 35.3 | 20.8% | 30.7% | +8.9% | +27% / +55% |
| BMYBristol-Myers Squibb Company | 131.2 bn | 14.2 | 44.1% | 18.5% | −0.2% | +30% / +30% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.4 | 6.6% | 3.6% | +4.3% | +56% / +326% |
| ZTSZoetis Inc. | 36.9 bn | 14.7 | 64.4% | 27.5% | +2.3% | −30% / −50% |
| ROIVRoivant Sciences Ltd. | 27.6 bn | — | -6.2% | -3,535.0% | −71.6% | +84% / +300% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 25.9 bn | 23.0 | 19.1% | 38.6% | +10.6% | +25% / +154% |
| INSMInsmed Inc | 24.1 bn | — | -72.5% | -39.9% | +66.7% | −47% / +340% |
| VTRSViatris Inc. | 22.1 bn | — | -23.6% | -23.9% | −3.0% | +80% / +109% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.6 bn | 8.1 | 126.6% | 52.8% | +65.2% | −64% / −4% |
| ORKAOruka Therapeutics, Inc. | 6.7 bn | — | -18.2% | — | unavailable | +237% / +364% |
| IONSIonis Pharmaceuticals, Inc. | 6.7 bn | — | -105.5% | -64.7% | +33.8% | −51% / −19% |
| AMRNAmarin Corp Plc\uk | 5.2 bn | — | -4.2% | -10.9% | −6.5% | −23% / −21% |
| IDYAIDEAYA Biosciences, Inc. | 3.1 bn | — | -38.5% | -1,149.6% | +3,024.4% | −9% / +3% |
| RADXRadiopharm Theranostics Limited | 3.1 bn | — | -109.2% | -1,055.3% | +1,114.3% | −81% / unavailable |
| AUPHAurinia Pharmaceuticals Inc. | 2.3 bn | 7.5 | 61.4% | 97.7% | +20.4% | +6% / +98% |
| QUREuniQure N.V. | 1.6 bn | — | -89.0% | -1,154.8% | −40.6% | −16% / +240% |
| URGNUroGen Pharma Ltd. | 1.4 bn | — | — | -26.3% | +21.4% | +45% / +148% |
1- and 3-year price returns: for URGN from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report04 Nov 2026
- Current report04 Nov 2026Results of operations · Financial statements and exhibits
- Current report20 Aug 2026Other events
- Quarterly report05 Aug 2026
- Current report05 Aug 2026Results of operations · Financial statements and exhibits
- Current report23 Jun 2026Item 3.03 · Departure or appointment of officers · Shareholder vote · Financial statements and exhibits
- Current report02 Jun 2026Other events
- Quarterly report06 May 2026
- Current report06 May 2026Results of operations · Financial statements and exhibits
- Proxy statement30 Apr 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.